Urologix Inc
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides P… Read more
Market Cap & Net Worth: Urologix Inc (ULGX)
Urologix Inc (PINK:ULGX) has a market capitalization of $2.18K ($2.18K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #51205 globally and #15909 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Urologix Inc's stock price $0.00 by its total outstanding shares 21817726 (21.82 Million).
Urologix Inc Market Cap History: 2015 to 2025
Urologix Inc's market capitalization history from 2015 to 2025. Data shows change from $187.63K to $2.18K (-46.46% CAGR).
Urologix Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Urologix Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ULGX by Market Capitalization
Companies near Urologix Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Urologix Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Urologix Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Urologix Inc's market cap moved from $187.63K to $ 2.18K, with a yearly change of -46.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $2.18K | 0.00% |
| 2024 | $2.18K | 0.00% |
| 2023 | $2.18K | 0.00% |
| 2022 | $2.18K | 0.00% |
| 2021 | $2.18K | -97.67% |
| 2020 | $93.82K | -4.44% |
| 2019 | $98.18K | -35.71% |
| 2018 | $152.72K | +438.46% |
| 2017 | $28.36K | +18.18% |
| 2016 | $24.00K | -87.21% |
| 2015 | $187.63K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Urologix Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.18K USD |
| MoneyControl | $2.18K USD |
| MarketWatch | $2.18K USD |
| marketcap.company | $2.18K USD |
| Reuters | $2.18K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.